The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis

Area of Science:

• Psychiatry
• Clinical Psychology
• Pharmacology

Background:

• Psychedelic-assisted therapy shows promise for treating depression.
• Study design in psychedelic trials can influence outcomes like blinding and participant expectations.
• Variations in study designs may lead to biased estimations of treatment effects.

Purpose of the Study:

• To examine the association between antidepressant efficacy and different study designs in psychedelic trials.
• To assess how factors like blinding and expectancy affect treatment outcomes.
• To identify potential biases in estimating the antidepressant effects of psychedelics.

Main Methods:

• Systematic search of six databases for eligible psychedelic trials.
• Inclusion criteria: oral psychedelic-assisted therapy (psilocybin, LSD, MDMA, ayahuasca) for adult depression, without concomitant antidepressants.
• Analysis of five study designs: non-active-drug-as-placebo, active-drug-as-placebo, waitlist-as-control, fixed-order, and pre-post designs.

Main Results:

• Psilocybin and MDMA showed significant antidepressant effects in non-active-drug-as-placebo designs.
• No statistically significant antidepressant effects were found for psilocybin or MDMA in active-drug-as-placebo designs.
• Psilocybin and ayahuasca demonstrated large effect sizes in pre-post single-arm and waitlist-control designs; LSD showed effects in non-active-drug-as-placebo designs.

Conclusions:

• The antidepressant effects of psychedelics may be overestimated in studies using pre-post single-arm, non-active-drug-as-placebo, and waitlist-control designs.
• Limitations such as small sample sizes, challenges in blinding, and participant expectancy can impact effect size estimations.
• Further research with robust methodologies is needed to accurately determine the efficacy of psychedelic-assisted therapies.